Caroline Bernardo Gusmão

Ms. Caroline Bernardo Gusmão

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2026 in Animals
Verified
Journal Article
Open access
PDF file
AJAmanda Junqueira
Amanda Junqueira
MMMaria Paula Luchi da Silva Mattos
Maria Paula Luchi da Silva Mattos
FHFrancine Hergemoller
Francine Hergemoller
TMThayse Meyer
Thayse Meyer
CGCaroline Bernardo Gusmão
Caroline Bernardo Gusmão
MFmarcio ferreira
marcio ferreira
This prospective, analytical study aimed to measure and compare trochlear groove depth using skyline radiographic projection and ultrasonography at three stifle joint angles and four distinct anatomical regions, as well as to compare these findings with ex vivo measurements obtained using a caliper under the same conditions in canine cadavers without patellar luxation. A total of 67 limbs were evaluated. Ultrasonography demonstrated greater agreement with ex vivo measurements than radiography. Ultrasonographic assessment was considered appropriate for measuring trochlear groove depth with the stifle joint in maximal extension, with the transducer positioned distal to the patella, and at 90° of flexion, with the transducer positioned proximal to the patella.

6 November 2026 in Veterinary Research Communications
Verified
Journal Article
Open access
PDF file
TNTaís Bock Nogueira
Taís Bock Nogueira
JLJosé Lucas Xavier Lopes
José Lucas Xavier Lopes
FSFrederico Aécio Carvalho Soares
Frederico Aécio Carvalho Soares
DSDenise Iparraguirre da Silva
Denise Iparraguirre da Silva
CGCaroline Bernardo Gusmão
Caroline Bernardo Gusmão
ÁPÁlan Gomes Pöppl
Álan Gomes Pöppl
This study evaluated adjunctive dapagliflozin therapy in insulin-treated diabetic dogs to assess short- and long-term glycemic, clinical, and laboratory outcomes in dogs with naturally occurring diabetes mellitus. Six diabetic dogs received a compounded liquid oral dapagliflozin (CLODapa) formulation (0.088 ± 0.013 mg/kg once daily) in addition to ongoing insulin therapy for 100 days. We monitored continuous glucose monitoring (CGM) before and after treatment initiation, and serially assessed clinical, biochemical, and urinary parameters. Short-term dapagliflozin administration significantly reduced mean interstitial glucose, glucose nadir and peak values, and increased time within the target glucose range (60–250 mg/dL), while decreasing time above range. Glycemic variability increased, although time spent < 60 mg/dL and clinical hypoglycemia did not increase; however, CLODapa’s initial dosage was reduced in four dogs due to concerns about hypoglycemia, increased in one, and left unchanged in another. Long-term treatment was associated with reductions in fructosamine, systolic blood pressure, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and cholesterol concentrations. No evidence of diabetic ketoacidosis, urinary tract infection, electrolyte imbalance, or acid–base disturbance was detected. Unintentional weight loss was documented in three patients and required a ~ 25% increase in food intake. Adjunctive dapagliflozin showed promise in improving glycemic control in diabetic dogs despite posing a risk of hypoglycemia, supporting further investigation of SGLT2 inhibition in canine diabetology.